Shares of PureTech Health plc (LON:PRTC – Get Free Report) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 125.47 and traded as low as GBX 108. PureTech Health shares last traded at GBX 108, with a volume of 774,681 shares.
Wall Street Analysts Forecast Growth
Separately, Peel Hunt restated a “buy” rating and issued a GBX 508 price target on shares of PureTech Health in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, PureTech Health has an average rating of “Buy” and a consensus price target of GBX 508.
Check Out Our Latest Stock Analysis on PRTC
PureTech Health Price Performance
About PureTech Health
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
Featured Stories
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
